Esperion Therapeutics Inc (NASDAQ:ESPR) major shareholder Target N. V. Biotech purchased 50,000 shares of the business’s stock in a transaction that occurred on Thursday, July 12th. The stock was acquired at an average price of $41.77 per share, for a total transaction of $2,088,500.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of Esperion Therapeutics opened at $42.35 on Friday, according to Marketbeat. The company has a market cap of $1.13 billion, a PE ratio of -6.07 and a beta of 2.37. Esperion Therapeutics Inc has a 12 month low of $33.06 and a 12 month high of $82.68.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.17). During the same period last year, the business earned ($1.80) EPS. research analysts forecast that Esperion Therapeutics Inc will post -6.31 earnings per share for the current fiscal year.

Several brokerages recently weighed in on ESPR. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. ValuEngine downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. UBS Group set a $75.00 price target on shares of Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 16th. JPMorgan Chase & Co. downgraded shares of Esperion Therapeutics from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $100.54 to $41.00 in a report on Thursday, May 3rd. Finally, Bank of America reiterated an “underperform” rating on shares of Esperion Therapeutics in a report on Wednesday, May 2nd. Three analysts have rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $89.08.

Several hedge funds and other institutional investors have recently modified their holdings of ESPR. Teacher Retirement System of Texas acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $458,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $222,000. Bank of New York Mellon Corp grew its stake in shares of Esperion Therapeutics by 0.7% during the 4th quarter. Bank of New York Mellon Corp now owns 116,224 shares of the biopharmaceutical company’s stock worth $7,652,000 after purchasing an additional 852 shares during the period. Alliancebernstein L.P. grew its stake in shares of Esperion Therapeutics by 40.0% during the 4th quarter. Alliancebernstein L.P. now owns 34,970 shares of the biopharmaceutical company’s stock worth $2,302,000 after purchasing an additional 10,000 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Esperion Therapeutics by 49.0% during the 4th quarter. Deutsche Bank AG now owns 175,787 shares of the biopharmaceutical company’s stock worth $11,571,000 after purchasing an additional 57,800 shares during the period. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.